The Broad Institute, Janssen Biotech and Massachusetts General Hospital have divulged new serine/threonine-protein kinase SIK2 (QIK) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.
The Universite Catholique de Louvain has described polypeptides acting as lactate dehydrogenase (LDH) tetramerization inhibitors reported to be useful for the treatment of cancer.
Korea Research Institute of Chemical Technology (KRICT) and PINOTBIO have patented benzothiazole and benzimidazole derivatives acting as NAD-dependent protein deacetylase sirtuin-7 (SIRT7) inhibitors reported to be useful for the treatment of cancer, among other disorders.
PharminoGen has presented prazole-carboxamide derivatives acting as cannabinoid CB1 receptor antagonists reported to be useful for the treatment of non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, dyslipidemia and diabetes.
Ascentage Pharma has discovered sulfonyl benzamide derivatives acting as apoptosis regulator Bcl-2 and/or Bcl-2 (G101V mutant) inhibitors reported to be useful for the treatment of cancer.
The Consiglio Nazionale delle Ricerche and the Societa Industria Farmaceutica Italiana SpA (SIFI) have described new peptides acting as vascular endothelial growth factor receptor 1 (VEGFR-1; FLT1) and VEGFR-2 inhibitors reported to be useful for the treatment of cancer, choroidal neovascularization, hematopoiesis disorders, macular edema, central retinal vein occlusion, central serous retinopathy, diabetic retinopathy and wet macular degeneration, among other disorders.
Yangtze River Pharmaceutical Group and Shanghai Haiyan Pharmaceutical Technology have divulged new morpholine derivatives acting as P2X purinoceptor 3 (P2RX3; P2X3) antagonists and reported to be useful for the treatment of cancer, pain, cough, depression, anxiety and genitourinary, gastrointestinal and immunological disorders, among other disorders.
RSS